CLINICAL TRIALS PROFILE FOR LOPERAMIDE HYDROCHLORIDE

All Clinical Trials for LOPERAMIDE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003057 ↗	Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer	Completed	Cancer and Leukemia Group B	Phase 3	1996-11-01	RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00003057 ↗	Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1996-11-01	RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00003057 ↗	Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer	Completed	Southwest Oncology Group	Phase 3	1996-11-01	RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00003057 ↗	Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer	Completed	Eastern Cooperative Oncology Group	Phase 3	1996-11-01	RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00129506 ↗	Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion	Completed	Ibis Reproductive Health	Phase 4	2005-05-01	Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
NCT00129506 ↗	Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion	Completed	Wiebe, Ellen, M.D.	Phase 4	2005-05-01	Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.

Clinical Trial Conditions for LOPERAMIDE HYDROCHLORIDE

Condition Name

Condition Name for LOPERAMIDE HYDROCHLORIDE
Intervention	Trials
Diarrhea	11
Fecal Incontinence	7
Breast Cancer	6
Healthy	4

Condition MeSH

Condition MeSH for LOPERAMIDE HYDROCHLORIDE
Intervention	Trials
Diarrhea	28
Breast Neoplasms	14
Irritable Bowel Syndrome	8
Fecal Incontinence	7

Clinical Trial Locations for LOPERAMIDE HYDROCHLORIDE

Trials by Country

Trials by Country for LOPERAMIDE HYDROCHLORIDE
Location	Trials
United States	228
Spain	17
Canada	10
China	9
Mexico	7

Trials by US State

Trials by US State for LOPERAMIDE HYDROCHLORIDE
Location	Trials
California	14
Texas	13
Florida	13
New York	12
North Carolina	11

Clinical Trial Progress for LOPERAMIDE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for LOPERAMIDE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for LOPERAMIDE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	35
RECRUITING	15
Terminated	9

Clinical Trial Sponsors for LOPERAMIDE HYDROCHLORIDE

Sponsor Name

Sponsor Name for LOPERAMIDE HYDROCHLORIDE
Sponsor	Trials
Puma Biotechnology, Inc.	4
Uniformed Services University of the Health Sciences	3
Napo Pharmaceuticals, Inc.	3

Sponsor Type

Sponsor Type for LOPERAMIDE HYDROCHLORIDE
Sponsor	Trials
Other	99
Industry	49
U.S. Fed	11

Loperamide Hydrochloride Clinical Trials Update, Market Analysis, and Launch-Era Patent/Exclusivity Projection

Last updated: July 30, 2026

Loperamide hydrochloride is an established antidiarrheal used globally in branded and generic forms. The near-term clinical-trial signal is mainly in incremental studies (new formulations, safety in specific populations, and real-world endpoints) rather than first-in-class innovation. Market growth is driven by continued OTC penetration, chronic GI symptom management, and expanding access in emerging markets, with competitive pressure from widespread generic availability.

What clinical trials are ongoing for loperamide hydrochloride and what endpoints are sponsors targeting?

Current trial activity is predominantly incremental. Across registries, loperamide studies cluster into: (1) pediatric and geriatric dosing/safety, (2) gastroenteritis-associated diarrhea outcomes, (3) pharmacokinetic or formulation comparisons (including modified-release concepts), and (4) safety surveillance in special-use scenarios (renal/hepatic impairment, elderly, and concomitant medications).

Pediatric safety and dosing trials: what do studies measure?

Sponsors typically target:

• Time to cessation of diarrhea episodes (or symptom score reductions)
• Stool frequency reduction over defined windows (for example, 24 hours)
• Adverse event rates, including CNS effects in high exposure settings
• Pharmacokinetics and exposure consistency across age bands

Formulation and bioequivalence: which trial types dominate?

Most recent additions tend to be:

• Bioequivalence studies for tablets/capsules or liquid presentations
• Comparative tolerability studies across brand formulations
• Studies testing faster onset, smoother symptom control, or altered-release profiles

Are there randomized efficacy trials versus placebo?

Where randomized placebo-controlled trials exist, they typically focus on:

• Acute infectious diarrhea or traveler’s diarrhea-like symptom frameworks
• Endpoints tied to stool frequency reduction and patient-reported outcomes

How large is the loperamide hydrochloride market and what segments drive revenue?

The market is mature and volume-led. Loperamide is sold as OTC and prescription products across diarrhea indications, with a strong skew toward:

• OTC retail in North America and Europe
• Hospital and institutional purchasing for acute diarrheal episodes
• Emerging market access growth as pharmacy networks expand

Segment map: by product form and distribution channel

• Oral solid dose: tablets, capsules (dominant in many markets)
• Oral liquid: pediatric dosing and OTC convenience in select geographies
• OTC: the majority of retail movement in the US and parts of Europe
• Institutional: emergency care and inpatient supportive therapy

Geographic dynamics

• North America and Western Europe: steady demand due to OTC consolidation; growth mostly tracks population and minor share shifts between formulations.
• Emerging markets: volume growth prospects are higher, supported by increased OTC availability and distribution reach.

Key demand drivers

• High treatment frequency for acute diarrhea episodes
• Broad guideline alignment for symptomatic management in appropriate settings
• Low barrier to adoption due to long-standing safety profile in labeled use

What is the loperamide hydrochloride clinical and competitive landscape by therapeutic class?

Loperamide is a symptomatic antidiarrheal (opioid receptor agonist acting in the gut). Competitive pressure comes from:

• Other antidiarrheals (bismuth subsalicylate, diphenoxylate-atropine in regions where available)
• Oral rehydration solution (ORS) and supportive care products (often the primary clinical intervention)
• Newer GI symptom products are typically adjunct rather than direct substitutes in many care pathways

Competitive positioning: why do prescribers still use loperamide?

• Rapid symptom control for non-bloody diarrhea
• Long OTC history and clinician familiarity
• Wide availability of generics

When does loperamide lose exclusivity and what does that mean for generics and price?

Exclusivity is effectively exhausted for most established loperamide presentations. Loperamide hydrochloride has long-standing generic availability, and the current market structure is dominated by multi-source manufacturing.

Patent estate reality check: what protects loperamide today?

For many markets:

• API composition-of-matter exclusivity is long expired.
• Remaining protection is typically limited to:
  • Specific formulations (if any active)
  • Manufacturing processes
  • Trademark and brand differentiation (commercial, not patent exclusivity)
  • Narrow method-of-use claims tied to specific dosing regimens or patient subsets, where still enforceable

Practical generic implications

• New entrants rarely face “entry-blocking” primary patents for standard loperamide dosage forms.
• Competitive differentiation tends to shift toward:
  • Controlled-release or alternative-release performance
  • Pediatric palatability and dosing accuracy
  • Safety labeling harmonization and pharmacovigilance programs

What Orange Book status exists for loperamide hydrochloride in the US?

Standard loperamide products have long since moved into a multi-generic environment. In the US, the key business implication is that most solid oral dosage forms and OTC equivalents are not protected by active, enforceable New Chemical Entity exclusivity.

What listings typically look like

• Many ANDA approvals for tablets/capsules and liquid presentations
• Limited remaining patent families tied to particular formulation improvements if they exist

Paragraph IV: is it a meaningful strategy for loperamide?

• For the core molecule, Paragraph IV challenges are usually low-impact because the market already has extensive generic coverage.
• Any challenge strategy is more likely to target narrow, still-listed formulation or method patents rather than the base API.

How do formulation patents and method-of-use claims affect the ability to launch a new loperamide product?

Most launch barriers are commercial and regulatory rather than IP at the API level. New product development tends to face:

• If listed patents exist for a particular formulation, launch timing depends on resolution or expiration of those narrow claims.
• If no active formulation patents exist, investors focus on ANDA readiness and cost-efficient manufacturing rather than litigation risk.

Common protected angles (where applicable)

• Modified-release designs that alter release kinetics
• Specific excipient systems for stability or GI delivery
• Specific dosing for subpopulations if a method-of-use patent is active (rare for loperamide given maturity)

What is the litigation and settlement landscape for loperamide hydrochloride?

Material loperamide patent litigation is not typically a dominant driver of market disruptions. Because generic competition is already established, enforcement risk is generally limited to:

• Occasional disputes tied to specific formulation patents, labeling claims, or distinct dosage technologies (where still listed and enforceable)

Business takeaway

For planning purposes, loperamide is best treated as:

• A low-IP-barrier product at the API and most mainstream dosage forms
• A market where switching costs are low and pricing pressure is persistent

What is the biosimilar or biologics risk for loperamide?

No biosimilar or biologics pathway is relevant. Loperamide is a small-molecule drug with conventional ANDA-style generics, not a biologic.

What FDA regulatory pathway applies to loperamide hydrochloride product launches?

ANDA is the typical route for generic solid oral and liquid loperamide products where bioequivalence can be established.

Labeling and safety constraints that influence launch

Key practical constraints include:

• Labeled indications (typically non-bloody diarrhea and appropriate supportive care context)
• Contraindications and warnings (notably safe use limits to avoid serious adverse outcomes in off-label high exposure situations)
• Pediatric labeling requirements that can affect formulation selection (liquid vs tablet, dosing precision)

Market projections: what growth rate and pricing outlook are realistic for loperamide hydrochloride?

Projection baseline: a mature, generic-dominant market with steady demand and modest value growth. Revenue growth is constrained by:

• Price compression from multi-source competition
• Substitution between pack sizes and generics

Revenue growth vs unit growth

• Unit growth can track population growth and OTC penetration in emerging markets.
• Revenue growth lags because price per unit trends downward.

Scenario framing for investors and R&D

• Base case: stable volume, gradual revenue normalization at low-single-digit growth.
• Upside case: faster OTC expansion in emerging geographies and incremental product performance improvements that win share.
• Downside: persistent pricing pressure, commoditization of formulations, and stronger retailer private-label penetration.

What R&D strategy is most credible for loperamide hydrochloride going forward?

The most credible R&D is incremental and formulation-led, not new mechanism:

• Modified-release or taste-masked pediatric liquid improvements
• Bioequivalence and manufacturing reliability programs
• Safety monitoring studies in label-relevant populations to support marketing claims and risk management

Where clinical trials add business value

• Demonstrating patient-relevant endpoints (rapid symptom relief and tolerability)
• Supporting differentiated labeling claims where regulatory frameworks allow
• Reducing adverse event risk via dosing accuracy and formulation improvements

Key Takeaways

• Clinical trial activity is mainly incremental: dosing/safety and formulation comparisons, not new mechanism breakthroughs.
• The market is mature, OTC-anchored, and driven by volume more than price.
• Patent exclusivity for loperamide’s core API is effectively exhausted; new launches face limited IP barriers at the base-drug level.
• Competitive pressure remains the central business factor, with differentiation most often tied to formulation, stability, and distribution.

FAQs

1. Do loperamide clinical trials focus more on pediatric safety or adult efficacy?
2. Which dosage forms for loperamide typically see the most demand: tablets, capsules, or liquids?
3. How does pricing pressure from multi-source generics usually affect loperamide revenue forecasts?
4. Are there any meaningful formulation patents that could delay a generic loperamide launch?
5. What regulatory pathway is most common for new generic or reformulated loperamide products in the US?

References

No sources were cited.